BioXcel Therapeutics, Inc. - BTAI
About Gravity Analytica
Recent News
- 03.11.2025 - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.11.2025 - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.11.2025 - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.07.2025 - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.07.2025 - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.07.2025 - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
- 03.04.2025 - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
- 03.04.2025 - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
- 03.04.2025 - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
- 03.03.2025 - BioXcel Therapeutics Announces $14 Million Registered Direct Offering